Home › Opioid Overdose › NCT04354077
Deep Brain Stimulation Effects In Patients With Opioid Use Disorder
Pilot Study to Evaluate Deep Brain Stimulation (DBS) of the Nucleus Accumbens (NAc) for Patients With Treatment-refractory Opioid Use Disorder
Who can join
Ages 22 to 65 · All sexes
Full eligibility criteria
Inclusion criteria 1. Male and females age ≥ 22 years with diagnosis of opioid use disorder (OUD) based on Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) with at least a 5-year history 2. OUD must be the primary disorder 3. History of ongoing or previous opioid use, relapse, and/or cravings, despite attempts at, or attendance in, at least two different treatment modalities. These modalities may include: Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient COAT, residential treatment, inpatient treatment, alternative to intensive outpatient programs, Drug Dependence Unit programs, medication-assisted treatment (MAT), medication assisted recovery (MAR), inpatient or outpatient rehabilitation, detox programs, Narcotics Anonymous, individual or group therapy, Partial Hospitalization Programs (PHP), Sober living homes, or similar interventions. 4. Self-reports ongoing opioid cravings. 5. Has completed a neuro-psychological evaluation to the satisfaction of a neuropsychologist 6. Has completed a psychiatric evaluation to the satisfaction of a psychiatrist 7. Has had a brain MRI performed and reviewed by neurosurgeon with no contraindication for DBS procedure identified 8. Platelet count \> 125,000 per cubic mm and prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits 9. Negative blood cultures to rule out bacteremia Exclusion criteria 1. Prior brain surgery contraindicating Deep Brain Stimulation (DBS) surgery, including procedures that required a craniotomy (e.g., brain tumor removal, trauma or pressure relief, hemorrhage, or clot evacuation). Patients with other brain surgery history will be considered and approved at the discretion of the Principal Investigator (PI). 2. Baseline assessment on the Hamilton Depression Rating Scale (HAMD) of greater than 17 or moderate risk of suicide based upon a score of 3 or greater on the Columbia Suicide Severity Scale, unless clinical judgment indicates that the individual is appropriate for inclusion despite these scores. 3. History of uncontrolled or persistent seizures 4. Suspected dementia based on neuropsychological screening or Mini Mental State Exam (MMSE) Score \< 25 5. Contraindications for MRI: 1. Presence of implanted electrical stimulation device or other implanted metal devices (excluding dental braces). 2. Claustrophobia 3. Body weight exceeding limit of the machine (180 kg/400 lb) 6. Females who are pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test during the pre-op phase and must agree to utilize adequate birth control throughout the trial and for at least 30 days following trial completion. 7. Coagulopathy secondary to chronic need for anticoagulation medicine (e.g. warfarin) or anti-platelet medication (e.g. aspirin or clopidogrel) 8. Diagnosis of neurological disorders (e.g. multiple sclerosis, Parkinson's disease, and stroke) 9. Severe brain atrophy or presence of subdural hygromas or subdural hematomas on brain MRI 10. Any evidence of underlying endocarditis. 11. Primary language other than English 12. Have any other medical condition that, in the opinion of the Investigator, makes the subject unsuitable for enrollment.
About the study
This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAc) as adjunctive treatment for treatment-refractory opioid use disorder. This study will include 3 individuals with opioid use disorder and relapsing opioid use despite active participation in a drug addiction treatment program.
What is being tested
- DBS of the NAc (device)
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Participants: 3 · Started: Feb 7, 2022
Contact the study team
- Nestor Tomycz, MD · Phone: 412-359-6200
- Donald Whiting, MD · Phone: 412-359-6200
Official record on ClinicalTrials.gov — NCT04354077
Locations in the U.S.
| Pennsylvania | AHN Allegheny General Hospital, Pittsburgh |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.